The obesity drug market is red-hot thanks to the huge success of Novo Nordisk's (NYSE:NVO) Ozempic and Wegovy. On Monday, Roche (RHHBY (OTC:RHHBY)) threw its hat into the ring with the $2.7...
- Day's Range
- 96.21 - 97.05
- 52 wk Range
- 64.45 - 105.69
- Prev. Close
- Average Vol.(3m)
- 1-Year Change
- Market Cap
- P/E Ratio
- United States
- Shares Outstanding
- Dividend (Yield)
- 1.4716 (0.76%)
- Next Earnings Date
- Jan 31, 2024
An analyst from Berenberg maintained Novo Nordisk B (CSE: NOVOb) at 'hold' with a price target of kr650.0 from a prior price target of kr610.0. Prior to this rating, Novo Nordisk B had...
An analyst from JPMorgan maintained Novo Nordisk B (CSE: NOVOb) at 'overweight' with a price target of kr850.0 from a prior price target of kr800.0. Prior to this rating, Novo Nordisk B...
One of TD Cowen's best ideas for 2024 has great expectations that are unlikely to disappoint, according to the firm's analysts in a recent research note.The firm said the company's momentum...
(Updated - December 4, 2023 9:30 AM EST) TD Cowen analysts raised the price target on Novo Nordisk (NYSE:NVO) to $115.00 (from $105.00) while maintaining an Outperform rating. The firm also...
Analysts at Cantor Fitzgerald initiated Novo Nordisk (NYSE:NVO) with an Overweight rating and a $120 per share price target in a note Friday.The analysts told investors that "the party is...
An analyst from Argus maintained Novo Nordisk ADR (NYSE: NVO) at 'buy' with a price target of $115.00 from a prior price target of $110.00. Prior to this rating, Novo Nordisk ADR had 3 buy...
Cantor Fitzgerald Starts Novo Nordisk at Overweight, 'runway for obesity remaining attractive for years to come'
(Updated - December 1, 2023 6:01 AM EST) Analysts at Cantor Fitzgerald initiate coverage on Novo Nordisk (NYSE:NVO) with a Overweight rating and a price target of $120.00.The analysts...
(Updated - November 27, 2023 1:12 PM EST) Main U.S. indexes were mixed on Monday ahead of the release of important inflation data this week. Retailers were on investors minds as holiday...
Investing.com -- Novo Nordisk (CSE:NOVOb) is ready to be "flexible" on pricing schemes for its Wegovy weight-loss drug as it attempts to make the blockbuster treatment more widely...
(Updated - November 24, 2023 12:21 PM EST) Main U.S. indexes were mixed on Friday, in thin trading with the session set to close early the day after the Thanksgiving holiday. The Dow Jones...
Investing.com - European stock markets traded in subdued manner Tuesday, as investors awaited the release of key European growth and U.S. inflation data. At 03:40 ET (08:40 GMT), the...
Investing.com -- U.S. stocks were wobbling on Monday, with last week’s positive sentiment diluted by Moody’s rating agency downgrading its outlook for the U.S. long-term credit...
Investing.com -- Novo Nordisk 's (NYSE:NVO) (CSE:NOVOb) blockbuster weight-loss drug Wegovy may have difficulty securing approval from Medicare for coverage as a heart disease treatment,...
Novo Nordisk (NYSE:NVO)'s obesity drug Wegovy, which contains the active ingredient Semaglutide, is now recognized for its direct cardiovascular benefits, not just its weight-loss effects....
In a recent breakthrough for Eli Lilly and Company (NYSE:LLY), its new weight loss drug, Zepbound, received approval from the Food and Drug Administration (FDA) on Wednesday. The drug...
Eli Lilly (NYSE:LLY)'s newly FDA-approved obesity treatment, Mounjaro, also known as Zepbound, has spurred a 3.2% rise in the company's stock on Wednesday. The drug, originally developed for...
Eli Lilly (NYSE:LLY) shares fell on Thursday after UnitedHealth (NYSE:UNH)'s Optum Rx said it will transition eight insulin products, produced by Eli Lilly, Novo Nordisk (NYSE:NVO), and...
An analyst from Stifel maintained Novo Nordisk B (CSE: NOVOb) at 'buy' with a price target of kr800.0 from a prior price target of kr760.0. Prior to this rating, Novo Nordisk B had 14...
An analyst from JPMorgan maintained Novo Nordisk B (CSE: NOVOb) at 'overweight' with a price target of kr800.0 from a prior price target of kr750.0. Prior to this rating, Novo Nordisk B...
An analyst from Morgan Stanley maintained Novo Nordisk B (CSE: NOVOb) at 'overweight' with a price target of kr730.0 from a prior price target of kr705.0. Prior to this rating, Novo...
Earnings call: Novo Nordisk Reports Strong Sales Growth, Raises Full-Year Outlook, and Advances R&D Pipeline
Novo Nordisk (NYSE:NVO), a global healthcare company specializing in diabetes and obesity treatments, reported robust sales and operating profit growth for the first nine months of 2023. The...
An analyst from Jefferies maintained Novo Nordisk B (CSE: NOVOb) at 'underperform' with a price target of kr430.0 from a prior price target of kr425.0. Prior to this rating, Novo Nordisk...
The Danish pharmaceutical company, Novo Nordisk (NYSE:NVO) A/S, has recently reported a successful 9-month period, marked by a significant net profit surge of 47%, reaching DKK 61.720...
Investing.com - Novo Nordisk ADR (NYSE: NVO) reported third quarter EPS of $5.00, $4.32 better than the analyst estimate of $0.68. Revenue for the quarter came in at $58.73B versus the...
(Updated - November 1, 2023 1:42 PM EDT) Novo Nordisk (NYSE:NVO) Has Hired Fujifilm Diosynth Biotechnologies To Fill Wegovy Injection Pens - ReutersNovo Nordisk has hired FUJIFILM Diosynth...
Pharmaceutical companies Novo Nordisk (NYSE:NVO) A/S, GSK Plc, Haleon Plc, and BASF SE (OTC:BASFY) are scheduled to announce their financial results next week amidst a range of market...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.